Erythroid response to treatment in eligible subjects at week 12
. | Arm A: rHuEPO + rHuG-CSF . | . | . | Arm B: supportive care . | ||
|---|---|---|---|---|---|---|
| . | Responders; n = 10 . | . | . | . | ||
. | Major response; n = 2 . | Minor response; n = 8 . | Nonresponders; n = 14 . | All subjects; n = 26 . | ||
| FAB classification, n | ||||||
| RA | 1 | 2 | 3 | 9 | ||
| RARS | 1 | 5 | 7 | 11 | ||
| RAEB | 0 | 1 | 4 | 6 | ||
| RBC transfusion dependent, n, yes/no | 0/2 | 3/5 | 14/0 | 24/2 | ||
| Hemoglobin concentration, g/L, mean ± SEM | 126 ± 5 | 98 ± 7 | 83 ± 13 | 88 ± 12 | ||
. | Arm A: rHuEPO + rHuG-CSF . | . | . | Arm B: supportive care . | ||
|---|---|---|---|---|---|---|
| . | Responders; n = 10 . | . | . | . | ||
. | Major response; n = 2 . | Minor response; n = 8 . | Nonresponders; n = 14 . | All subjects; n = 26 . | ||
| FAB classification, n | ||||||
| RA | 1 | 2 | 3 | 9 | ||
| RARS | 1 | 5 | 7 | 11 | ||
| RAEB | 0 | 1 | 4 | 6 | ||
| RBC transfusion dependent, n, yes/no | 0/2 | 3/5 | 14/0 | 24/2 | ||
| Hemoglobin concentration, g/L, mean ± SEM | 126 ± 5 | 98 ± 7 | 83 ± 13 | 88 ± 12 | ||
The mean hemoglobin concentration (± SEM) among all responders was 104 ± 13 g/L.